{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://minktherapeutics.com/#organization",
      "name": "MiNK Therapeutics, Inc.",
      "url": "https://minktherapeutics.com/",
      "description": "MiNK Therapeutics, Inc. MiNK Therapeutics is a cutting-edge clinical-stage company developing innovative allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The lead product is an off-the-shelf therapy administered without lymphodepletion or HLA matching. These cells enhance both innate and adaptive immunity by combining the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells. MiNK has treated over 70 patients with solid tumors and severe acute respiratory distress syndrome with exceptional efficacy. Moreover, MiNK has shown the potential to engineer and edit these cells for precision targeting, further"
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/minktherapeutics-com#asg",
      "name": "MiNK Therapeutics, Inc. ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/minktherapeutics-com",
      "isPartOf": {
        "@id": "https://minktherapeutics.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}